Benzodiazepines are generally considered safe for the heart and do not meaningfully prolong the QTc interval at normal clinical doses. A 2023 study of 251 patients at an addiction medicine unit in Verona found no significant relationship between QTc prolongation and benzodiazepine use, even among people taking high doses long-term. This puts benzos in a very different category from many other psychiatric medications, particularly antipsychotics and certain antidepressants, which carry well-documented QTc risks.
That said, the full picture has some nuance worth understanding, especially if you’re taking other medications or have existing heart concerns.
What QTc Prolongation Actually Means
The QT interval is the time it takes your heart’s lower chambers to electrically reset after each beat. When that interval stretches too long, there’s a brief window where the heart is vulnerable to a dangerous rhythm called torsades de pointes, a type of irregular heartbeat that can cause fainting or, rarely, sudden cardiac death. The upper limit of normal QTc is about 450 milliseconds in men and 470 milliseconds in women.
Many drugs prolong QTc by blocking a specific potassium channel in heart cells (called hERG) that helps the heart reset between beats. When this channel is blocked, the electrical reset takes longer, and the QT interval stretches. This is the mechanism behind QTc warnings on dozens of common medications.
Why Benzos Are Considered Low Risk
The Verona study used latent class analysis to group patients into three distinct profiles based on their substance use patterns and QTc risk. Across all three groups, benzodiazepine use itself was not associated with QTc prolongation. The researchers concluded that benzodiazepines, even when used chronically and at high doses, can be considered safe from a cardiovascular standpoint.
Separate clinical data supports this. A study examining the effects of intravenous midazolam (a short-acting benzodiazepine used for sedation) found it had no significant effect on the QTc interval. This is particularly telling because intravenous delivery produces much higher peak blood concentrations than oral dosing.
The Lab Data: A Weak Signal at Very High Concentrations
At the molecular level, there is a theoretical signal. Lab experiments showed that midazolam does block the hERG potassium channel, the same channel that known QT-prolonging drugs target. But the concentration required to block half of those channels was roughly 13.6 micromolar in human cell lines, a level far above what occurs during normal clinical use. The researchers characterized midazolam as a “low-affinity inhibitor” of these channels.
In practical terms, this means benzodiazepines can interact with the heart’s electrical system in a petri dish, but the doses required are so much higher than what reaches your heart during treatment that the effect is not clinically meaningful. The drug also did not interfere with how these channels are produced and transported to the cell surface, which is another mechanism by which some drugs cause QT problems over time.
Where Caution Still Applies
The picture gets more complicated with polydrug use. One review noted that QTc prolongation was associated with overdoses involving combinations of medications including benzodiazepines alongside opioids, certain antidepressants, and sleep aids. In overdose scenarios, blood levels of any drug can reach concentrations far beyond the therapeutic range, potentially crossing into territory where even low-affinity hERG blockers become relevant.
The Verona researchers specifically highlighted that not much is known about how benzodiazepines interact with other drugs when used chronically at high doses in polysubstance contexts. If you’re taking a benzodiazepine alongside a medication that has a known QTc risk (like certain antipsychotics, some antibiotics, or specific antidepressants), the combined effect on heart rhythm deserves attention even though the benzodiazepine alone would not be concerning.
Sex and age also matter. The Verona study emphasized the importance of considering QTc in older women specifically, who are already at higher baseline risk for QT prolongation regardless of medication use. Women have naturally longer QTc intervals, and aging further increases susceptibility.
How Benzos Compare to Other Psychiatric Medications
Benzodiazepines have a substantially better QTc safety profile than many alternatives used for anxiety, agitation, or sleep. Quetiapine, an antipsychotic sometimes prescribed for anxiety and insomnia, has documented associations with QTc prolongation and case reports of torsades de pointes. Haloperidol, frequently used for acute agitation, carries similar QTc risks. The CredibleMeds database, considered the gold standard for classifying drug-related QT risk, categorizes medications into tiers: known risk, possible risk, conditional risk, and drugs to avoid in congenital long QT syndrome. Common benzodiazepines are not prominently featured in the higher-risk categories.
This relative safety is one reason benzodiazepines remain a preferred option in acute settings when heart rhythm is a concern. For someone who needs sedation but is already on a QT-prolonging medication, a benzodiazepine is often a safer cardiac choice than adding a second QT-prolonging drug.
The Bottom Line on Cardiac Safety
At standard therapeutic doses, benzodiazepines do not prolong QTc to a clinically significant degree. The molecular interaction with heart potassium channels exists but requires drug concentrations far above what normal prescribing produces. The clearest risk scenarios involve massive overdose, combinations with other QT-prolonging drugs, or use in older women who may already be near the upper boundary of normal QTc. For the vast majority of people taking a prescribed benzodiazepine, QTc prolongation is not a meaningful concern.